GALNT7 and prostate cancer: GALNT7 levels were 7.7 fold higher in urine and 2.1 fold higher in plasma samples from men later diagnosed with prostate cancer compared to men with benign disease or a ‘no cancer’ diagnosis (Fig. 2A, B).